DexCom, Inc. Forecast, price target & analysts
DexCom, Inc. Target price 2025 - Analyst rating & recommendation
DexCom, Inc. Classifications & Recommendation:
DexCom, Inc. Price Target
| Target Price | $102.51 |
| Price | $86.33 |
| Potential | 18.74% |
| Number of Estimates | 29 |
| 29 Analysts have issued a price target DexCom, Inc. 2026 . The average DexCom, Inc. target price is $102.51. This is 18.74% higher than the current stock price. The highest price target is $120.75 39.87% , the lowest is $82.82 4.07% . | |
| A rating was issued by 33 analysts: 28 Analysts recommend DexCom, Inc. to buy, 5 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the DexCom, Inc. stock has an average upside potential 2026 of 18.74% . Most analysts recommend the DexCom, Inc. stock at Purchase. |
Sales and Margin forecast 2025, 2026 to 2030
31 Analysts have issued a sales forecast DexCom, Inc. 2025 . The average DexCom, Inc. sales estimate is $4.7b . This is 13.50% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $4.9b 19.07% , the lowest is $4.5b 7.93% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | $4.0b | 11.34% |
|---|---|---|
| 2025 | $4.7b | 16.74% |
| 2026 | $5.4b | 15.29% |
| 2027 | $6.2b | 14.61% |
| 2028 | $7.2b | 15.53% |
| 2029 | $7.9b | 10.00% |
| 2030 | $8.5b | 7.30% |
24 Analysts have issued an DexCom, Inc. EBITDA forecast 2025. The average DexCom, Inc. EBITDA estimate is $1.4b . This is 58.66% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $1.5b 72.65% , the lowest is $1.2b 34.53% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | $871m | 39.97% |
|---|---|---|
| 2025 | $1.4b | 56.22% |
| 2026 | $1.7b | 23.00% |
| 2027 | $2.0b | 21.80% |
| 2028 | $2.6b | 29.28% |
| 2029 | $3.0b | 15.36% |
| 2030 | $3.2b | 3.68% |
EBITDA Margin
| 2024 | 21.60% | 25.72% |
|---|---|---|
| 2025 | 28.91% | 33.83% |
| 2026 | 30.84% | 6.68% |
| 2027 | 32.78% | 6.29% |
| 2028 | 36.68% | 11.90% |
| 2029 | 38.46% | 4.85% |
| 2030 | 37.17% | 3.35% |
30 DexCom, Inc. Analysts have issued a net profit forecast 2025. The average DexCom, Inc. net profit estimate is $811m . This is 51.61% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $881m 64.62% , the lowest is $749m 40.00% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | $576m | 6.41% |
|---|---|---|
| 2025 | $811m | 40.82% |
| 2026 | $1.0b | 25.12% |
| 2027 | $1.3b | 23.16% |
| 2028 | $1.5b | 22.66% |
| 2029 | $1.8b | 16.62% |
| 2030 | $1.9b | 5.42% |
Net Margin
| 2024 | 14.29% | 4.43% |
|---|---|---|
| 2025 | 17.23% | 20.60% |
| 2026 | 18.70% | 8.53% |
| 2027 | 20.10% | 7.49% |
| 2028 | 21.34% | 6.17% |
| 2029 | 22.63% | 6.04% |
| 2030 | 22.23% | 1.77% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2030
30 Analysts have issued a DexCom, Inc. forecast for earnings per share. The average DexCom, Inc. EPS is $2.07 . This is 59.23% higher than earnings per share in the financial year 2024. The highest EPS forecast is $2.25 73.08% , the lowest is $1.91 46.92% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | $1.40 | 10.24% |
|---|---|---|
| 2025 | $2.07 | 47.86% |
| 2026 | $2.59 | 25.12% |
| 2027 | $3.19 | 23.17% |
| 2028 | $3.91 | 22.57% |
| 2029 | $4.56 | 16.62% |
| 2030 | $4.81 | 5.48% |
P/E ratio
| Current | 66.41 | 13.46% |
|---|---|---|
| 2025 | 41.72 | 37.18% |
| 2026 | 33.34 | 20.09% |
| 2027 | 27.07 | 18.81% |
| 2028 | 22.07 | 18.47% |
| 2029 | 18.92 | 14.27% |
| 2030 | 17.95 | 5.13% |
Based on analysts' sales estimates for 2025, the DexCom, Inc. stock is valued at an EV/Sales of 7.15 and an P/S ratio of 7.19 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 8.11 | 32.92% |
|---|---|---|
| 2025 | 7.15 | 11.87% |
| 2026 | 6.20 | 13.26% |
| 2027 | 5.41 | 12.75% |
| 2028 | 4.68 | 13.44% |
| 2029 | 4.26 | 9.09% |
| 2030 | 3.97 | 6.80% |
P/S ratio
| Current | 8.16 | 33.11% |
|---|---|---|
| 2025 | 7.19 | 11.89% |
| 2026 | 6.24 | 13.26% |
| 2027 | 5.44 | 12.75% |
| 2028 | 4.71 | 13.44% |
| 2029 | 4.28 | 9.10% |
| 2030 | 3.99 | 6.80% |
Current DexCom, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Truist Securities |
➜
Buy
|
Initiated | Jun 16 2025 |
| Goldman Sachs |
➜
Buy
|
Initiated | May 30 2025 |
| Citigroup |
Buy
➜
Buy
|
Unchanged | May 22 2025 |
| Barclays |
Equal-Weight
➜
Equal-Weight
|
Unchanged | May 05 2025 |
| Baird |
Outperform
➜
Outperform
|
Unchanged | May 02 2025 |
| Piper Sandler |
Overweight
➜
Overweight
|
Unchanged | May 02 2025 |
| Canaccord Genuity |
Buy
➜
Buy
|
Unchanged | May 02 2025 |
| Analyst Rating | Date |
|---|---|
|
Initiated
Truist Securities:
➜
Buy
|
Jun 16 2025 |
|
Initiated
Goldman Sachs:
➜
Buy
|
May 30 2025 |
|
Unchanged
Citigroup:
Buy
➜
Buy
|
May 22 2025 |
|
Unchanged
Barclays:
Equal-Weight
➜
Equal-Weight
|
May 05 2025 |
|
Unchanged
Baird:
Outperform
➜
Outperform
|
May 02 2025 |
|
Unchanged
Piper Sandler:
Overweight
➜
Overweight
|
May 02 2025 |
|
Unchanged
Canaccord Genuity:
Buy
➜
Buy
|
May 02 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
